Few studies on the distribution of oral diseases in older people are available in the literature. This study aimed to investigate the prevalence and demographic characteristics of oral and maxillofacial lesions in geriatric patients (age ≥ 60 years). A retrospective descriptive cross-sectional study was performed. Biopsy records were obtained from archives of three Brazilian oral pathology centers over a 20-year period. Data on sex, age, anatomical site, skin color, and histopathological diagnosis were collected and analyzed. Pearson’s chi-square test was used to evaluate differences in the frequency of the different oral and maxillofacial lesion groups. A total of 7,476 biopsy records of older patients were analyzed. Most cases were diagnosed in patients aged 60 to 69 years (n = 4,487; 60.0%). Females were more affected (n = 4,403; 58.9%) with a female-to-male ratio of 1:0.7 (p < 0.001). The tongue (n = 1,196; 16.4%), lower lip (n = 1,005; 13.8%), and buccal mucosa (n = 997; 13.7%) were the most common anatomical sites. Reactive and inflammatory lesions (n = 3,840; 51.3%) were the most prevalent non-neoplastic pathologies (p < 0.001), followed by cysts (n = 475; 6.4%). Malignant neoplasms were more frequent (n = 1,353; 18.1%) than benign neoplasms (n = 512; 6.8%). Fibrous/fibroepithelial hyperplasia (n = 2,042; 53.2%) (p < 0.001) and squamous cell carcinoma (n = 1,191; 88.03%) (p < 0.001) were the most common oral lesions in older adults. Biopsy data allow the accurate characterization of the prevalence of oral and maxillofacial lesions, supporting the development of public health policies that can enable the prevention, early diagnosis, and appropriate treatment of these lesions. Also, they bring valuable information that helps dentists and geriatricians diagnose these diseases.
Objective: To determine the prevalence and clinical profile of treatment‐related adverse events (TRAE) associated with: (1) botulinum toxin in the upper face; (2) hyaluronic acid fillers in the lower face and nasolabial folds; and (3) nonsurgical facelifts with absorbable threads. Methods: Searches were conducted in five electronic databases and gray literature. Proportion meta‐analyses were performed to estimate the prevalence of TRAE for each type of aesthetic procedure. Results: 42 studies were included. TRAEs were reported in 34.8% of included patients. The highest TRAEs prevalence was associated with hyaluronic acid fillers (63.0%, 95% CI: 35%–84%), followed by nonsurgical facelifts with absorbable threads (20.0%, 95% CI: 8%–41%) and botulinum toxin in the upper face (18.0%, 95% CI: 10%–32%). The most frequently reported TRAEs were swelling (22.4%) and pain (19.0%) for hyaluronic acid fillers; pain (31.5%) and bruising (23.4%) for nonsurgical facelifts with threads; and headache for botulinum toxins. Hyaluronic acid fillers accounted for 67.3% of all TRAEs ( n = 3729/4971). Conclusions: The overall prevalence of adverse events was low for botulinum toxin and thread lifts, but high for hyaluronic acid fillers. Future studies should report all adverse events, expected and not expected, detailing the number of patients affected, total events, onset and recovery times, severity, and provider category.